Indication for Surgery in Endometrial & Cervical Cancer. everything you need to know in 30 minutes!!! Fabio Landoni, MD Gynecologic Department
|
|
- Sara Welch
- 5 years ago
- Views:
Transcription
1 Indication for Surgery in Endometrial & Cervical Cancer everything you need to know in 30 minutes!!! Fabio Landoni, MD Gynecologic Department
2 Risk Factors LVSI Myometrial invasion Nodes grade Adjuvant Hysto type stage
3 Initial clinical findings
4 Primary treatment Disease limited to the uterus (endometrioid histologies)
5 520 patients, stage I endometrial cancer median follow-up of 70 months - Operating time and blood loss were statistically significantly higher for class II hysterectomy. - 5-year DFS and OS were similar between arms 87.7 and 88.9% in the class I arm and 89.7 and 92.2% in the class II arm Hazard ratio for recurrence: 0.91 (95% confidence interval, , P = 0.72) Hazard ratio for death: 0.77 (95% confidence interval, , P = 0.35) Class II hysterectomy did not improve locoregional control and survival compared to class I hysterectomy (EBMa)
6 Treatment trends vs survival in Stage II SEER DATA on ENDOMETRIAL CANCER Hysterectomy Simple Radical N. 5yrsurv 5yrsurv N. No radiation % % p<0.05 Plus radiation % % p<0.05 Cornalison (SGO 1999)
7 - 8 RCT met the inclusion criteria women were assessed
8
9 Primary treatment Disease limited to the uterus (endometrioid histologies)
10 Take home message Although, no longer a part of the current FIGO staging criteria, peritoneal cytology status should still be considered for -accurate 14,704 stage risk-stratification I/II endometrial cancer of these whopatients had undergone a complete staging procedure (lymph-node removal) were included -survival was significantly worse among patients with positive peritoneal cytology (p<0.0001): 5-year disease specific survival 95.1% vs. 80.8% (endometrioid) 78.0% vs. 50.4% (clear cell/serous) PPC is an independent risk factor in patients with early stage endometrial cancer
11 Hot topic: linfadenectomy when? Different therapeutic strategies are compared 1) Extensive surgical staging with restrictive use of post-operative radiotherapy 2) Surgery limited to extrafascial hysterectomy with bilateral oophorectomy and more extensive use of postoperative radiation therapy 3) Intermediate strategy with the aid of frozen section to limit the number of lymphadenectomy
12 Current clinical practice Survey, SGO members Respondent rate 50 % (N = 406) LN staging G1 35 % G2 66 % G3 90 % Cranial anatomical border IMA 50 % renal vessels 11 % Gynecol Oncol, 2010, 119,
13 Can they answer our questions?
14 Can they answer our questions? 13% Overall of positive lymph nodes IA-IB G1 (45% of all cases) 9% Overall positive lymph nodes
15 Limited Extent of Lymphadenectomy Iliac and Pelvic LND: at least 20 nodes required Median Number of pelvic nodes = 26 Paraaortic LND at the discretion of the MD (performed in 26%) obturator nodes Median Number of Nodes = 12 35% less than 10 nodes Paraortic LND at the discretion of the physician
16 NO SURVIVAL BENEFIT Pelvic LND/sampling alone does not improve survival Patients at low risk for N+ do not need LND Do high risk patients benefit from PPALND?
17 Cochrane Lymphadenectomy for EC No evidence that lymphadenectomy decreases the risk of death or disease recurrence compared with no lymphadenectomy in women with presumed stage I disease. The evidence on serious adverse events suggests that women who receive lymphadenectomy are more likely to experience surgically related systemic morbidity or lymphoedema/lymphocyst
18 Meta-analysis 9 studies LR (2 RCT + 7 obs) N = HR JCO, 2012, 42,
19 Mayo criteria for low risk EC type I histology - grade 1 or 2 - MI 50 primary tumor diameter 2 cm Conclusion: Lymphadenectomy dramatically increases morbidity and cost of care without discernible benefits in low-risk EC as defined by the Mayo criteria
20 CONCLUSIONS Although SLN biopsy has shown good diagnostic performance in endometrial cancer, such performance should be interpreted with caution because of significant small study effects. Current evidence is not yet sufficient to establish the true performance of SLN biopsy in endometrial cancer.
21 ENDOMETRIAL CANCER: tailoring the surgical approach - Low risk: G1-G2 < 50% MI Hysterectomy with bilateral salpingooophorectomy (EBMa) - Intermediate risk: G2 > 50%, G3 < 50% Hysterectomy with bilateral salpingooophorectomy and pelvic lymphadenectomy. (EBMb)
22 ENDOMETRIAL CANCER: tailoring the surgical approach - High Risk: Grade 3 tumors and/or deep (>50%) myometrial invasion, and/or cervical stromal spread: +Radical hysterectomy with bilateral salpingo-oophorectomy, pelvic and para-aortic lymphadenectomy. (EBMc)
23 Esmo guidelines
24 Role of surgery in Cervical Cancer stage by stage
25 Stage IA1 Conization (EBMb): If the depth of invasion is less than 3 mm, no vascular or lymphatic channel invasion is noted, and the margins of the cone are negative, conization alone may be appropriate in patients wishing to preserve fertility Total hysterectomy (EBMb): if the depth of invasion is less than 3 mm (proven by cone biopsy) with clear margins and no vascular or lymphatic channel invasion is noted, the frequency of lymph node involvement is sufficiently low that lymph node dissection is not required. Oophorectomy is optional and should be deferred for younger women.
26 Stage IA2 Modified radical hysterectomy (EBMc): For patients with tumor invasion between 3 mm and 5 mm, radical hysterectomy with pelvic node dissection has been recommended because of a reported risk of lymph node metastasis of as much as 10% Radical hysterectomy (EBMc) with node dissection may also be considered for patients where the depth of tumor invasion was uncertain because of invasive tumor at the cone margins ( FIGO-IGCS committee 2003)
27 Lymphadenectomy in C.C. Incidence of node metastasis by stromal invasion 3-5mm ( ) Author Hasumi 1980 Van Nagel 1983 Simon 1986 Maiman 1988 Buckley 1996 Creasman 1998 Total N pts nodal mets (%) (13) 3 (9,4) 1 (3,8) 4 (13) 7 (7,7) (7,3) inv rec DOD not stadet not stadet (3,1) 6 (2,3%) Some studies have included tumors with horizontal spread >7mm or clinical lesion
28 Lymphadenectomy in C.C. Incidence of node metastasis by FIGO IA2 ( ) Author N pts nodal mets (%) inv rec DOD 2 (2,5%) 0 not stadet Ostor 1994 Creasman 1998 CTF 2003 Ceballos 2006 Poynor 2006 Lee 2006 Bisseling (3,7%) 0 3 (3,8) 0 3(13%) Total (0,5) 6 (2,9) 2 (1%) 10% operative morbidity, 1% ureteric injury, 7% lymphedema suggest that the complication of Radical surgery outweigh the benefits
29 NIH Consensus Statement on C.C. Bethesda 1996 patients with stage IB and IIA cervical cancer are appropriately treated with either radical hysterectomy with pelvic lymphadenectomy or radiation therapy with equivalent result. To minimize morbidity, primary therapy should avoid the routine use of both radical surgery and radiation therapy therapy.. The combined use of radical surgery and radical radiation therapy results in high morbidity and cost cost..
30 Radical hysterectomy vs. radiotherapy in stage IB Landoni F et al, Lancet 350:535, 1997
31 Stage Ib1- IIa1 Younger patients may benefit from surgery in regard 1) ovarian preservation 2) conservative
32 Ovarian metastases in cervical cancer patients 1695 pts with BSO -multivariate analisys Ovarian mets parameter 16pts odds ratio 0,9% 95% CL p FIGO stage Histology Space uninv < (EMBb) Landoni F et al, I.J.G.C,2007
33 Our own guidelines to preserve the ovaries in R.S. Women 40 years old or younger No morphological abnormality in the ovary Stage FIGO 1a2 1b1 IIa1 Squamous, >3mm uninvolved tissue (MRI) No hystory of breast cancer No risk of familial ovarian cancer (salpingectomy)
34 Conservative Treatment in Early Stage CC
35 Laparoscopic pelvic lymphadenectomy & VRT Reference Stage Relapses SCC Adeno Other Sheperd IA2-IB1 3/112 ND ND ND Hertel IA1-IB1 4/108 1/75 3/33 -- Mathevet IA1-IIA 4/95 3/76 1/19 1/1* Covens IA1-IB1 7/93 4/40 3/50 -- Plante IB1 3/72 1/42 1/30 1/1* Sonoda IA1-IB1 1/36 ND ND ND Burnett IB1 0/ Schlaert IA2-IB1 0/ * excluded TOTAL 22/545 (4%) Beiner & Covens 2007
36 Laparoscopic pelvic lymphadenectomy & VRT < 2 cm Sheperd Relapses > 2 cm ND ND 3/107 1/1 Mathevet 0/74 4/21 Covens 6/85 1/8 Plante 0/64 2/8 Sonoda ND ND Burnett ND ND Schlaert ND ND 9/ % 8/38 21% Hertel TOTAL
37 RVT Obstetric outcomes Pregnancy rates of 41-79% 208 reported pregnancies, which resulted in 134 (64%) third trimester live births The rate of first trimester miscarriage was 18% The rate of second trimester miscarriage was 10% The rate of preterm delivery (< 37 weeks) was 20%
38 RVT KEY POINTS (EBMc) Safe and feasible procedure to perform in early-stage small volume cervical cancers The tumor recurrence rate and the mortality rate are comparable to those observed after radical surgery Lesion size > 2cm is probably the most important risk factor for recurrence Taking home message! The operation has an acceptable complication profile but is associated with a significant incidence of miscarriage and premature labour. In stage IA2 should be offered a more conservative approach with large conisation & pelvic node dissection.
39 How radical should surgery be In stage Ib1 cervical cancer is the removal of parametria always necessary?
40 IA2,IB1- < 2 cm, <½ of stromal invasion parametrial involvement? How many LN negative pts have positive findings in the medial part of parametrium? Rob et al retrospective study 40 IA2, 85 IB1 Covens et al retrospective study 3/536 Steed et al retrospective study 0/120 Plante et al radical trachelectomy 0/76 Stegeman et al retrospective study 5/799 - PI - 0% - PI - 0,6% - PI - 0% - PI - 0% - PI % Strnad P., Rob L et al prospective SLNM study 133 SLN neg. - PI - 0% 25 SLN posit. - PI - 28%!! Gynecologic Oncology 1O9 (2008)
41
42 The SHAPE Trial: Simple Hysterectomy And Pelvic node dissection in Early cervix cancer Comparing radical hysterectomy and pelvic node dissection against simple hysterectomy and pelvic node dissection in patients with low risk cervical cancer Chair: Marie Plante University of Laval, Quebec City An NCIC Clinical Trials Group proposal for the Gynecological Cancer Inter Group (GCIG)
43 IEO Experience Tumor diameter < 2 cm (>/= 1cm from IUO) Laparoscopically pelvic LA & Simple trachelectomy NEGATIVE NODES F-UP if no evidence of risk factors risk factors (LVS+,<3mm safe, 2cm) chemo x3 Tumor diameter > 2 < 3 cm (>/= 1cm from IUO) Laparoscopically pelvic LA NEGATIVE NODES Platinum&taxol-based chemotherapy for 3 cycles Simple trachelectomy/cervical cone Landoni Gyn Oncol. 2007
44 All patients (n=34) FIGO st Drop-out N+ (n=4) Conservative treatment (n=30 ) Cervical cone (n=29) Adjuvant Chemo (n=6) Chemo: TEP 3 pts Carbo-taxolo 4 pts Histo IA2 9 IB1 21 SCC 21 AdeK 9 NACTH (n=1/ TEP/ pcr) Relapses (n=0) Demolitive surgery (pts desire n=5)
45 Attempt to conceive (%) 14/30 (46.7) Clinical pregnancy rate / pts (%) (2 pts after chemo) 10/14 (71.4) Abortion 1/12 Ectopic preg. 1/12 Ongoing -/- LBR 10/12 (83)
46 Simple Cone & lymphadenectomy in st IB1<2cm Italian Experience (IEO/CUSH-Rome/Monza) Follow-up:66m. (range ) Hysterectomy: 5 pts after 3-12 yrs (1pt microinv adk) Gyn.Onc. 2011, 123(3):557-60
47 Clinical pregnancy rate / pts (%) 15/17 (88.2) I trim miscarriages 3/17 II trim miscarriages 1/17 Ectopic preg. 1/17 Ongoing 1/17 LBR 14/17 (82.3)
48 PRO These data demonstrate that simple trachelectomy / cervical cone can be safely performed. Data are comparable with more radical procedure Pregnacies rate is slightly better than RVT CONS (EBMc) Low compliance Chemo-cone: alopecia & theoretical teratogenicity Endocervical involvement: isthmic surveillance (IUO preserved)
49 How radical should surgery be Radical hysterectomy is not a single operation. Many variations exist, for which there is no standard terminology and no standard description.
50 The Four Types of Radical Hysterectomy Class A : minimum resection of paracervix Class B : transection of the paracervix at the ureter Class C : transection of the paracervix at the hypogastric junction Class D : laterally extended resection Morrow & Querleu
51 Pelvic Anatomy Peham-Amreich diagram
52 Surgery in cervical cancer R A D I C A L I T Y Type C2 D1 Type C1 Type B1-2 S E Q U E L A E Compromised sexual function Decreased lubrification & genital swelling Bladder & Bowel dysfunction
53 (EBM a)
54 ISSUES NOT DISCUSSED in surgical management of CC - RADICAL SURGERY in locally advanced - NACTH to surgery in locally advanced (EORTC trial 55994) - Pelvic Exenteratio
55
56
57 Algoritm for st Ib2-IIA2 100 pts Node neg Node pos 71 pts 29 pts Pelvic pos 15 High Risk 24,6pts(85%) Pelvic/LLAA pos LLAA pos 4pts (13,8%) 0,4pts (1,2%) RT Geographic omission
58 SURGICAL vs CLINICAL STAGING RECOMMENDATIONS FOR LACC Use PET/CT when available for treatment planning Resect bulky nodes not amenable for radiation therapy if feasible
59 THANKS FOR THE ATTENTION!!!
ESGO-ESTRO-ESP Cervical Cancer Clinical Practice Guidelines Management of early stages: algorithms focusing on the histological data
ESGO-ESTRO-ESP Cervical Cancer Clinical Practice Guidelines Management of early stages: algorithms focusing on the histological data David Cibula Gynecologic Oncology Centre General University Hospital
More informationsurgical staging g in early endometrial cancer
Risk adapted d approach to surgical staging g in early endometrial cancer Leon Massuger University Medical Centre St Radboud Nijmegen, The Netherlands Doing nodes Yes Yes Yes No No No 1957---------------------------
More informationGynecologic Cancer InterGroup Cervix Cancer Research Network. The SHAPE Trial
Gynecologic Cancer InterGroup Cervix Cancer Research Network The SHAPE Trial Comparing radical hysterectomy and pelvic node dissection against simple hysterectomy and pelvic node dissection in patients
More informationRochester Minnesota Mayo Clinic
Are There Still Indications for Lymphadenectomy in Endometrial Cancer? A Mariani Mayo Clinic Rochester - MN USA Rochester Minnesota Mayo Clinic 1 Endometrial Cancer Lymphadenectomy Yes or No? Endometrial
More informationRole of Surgery in Cervical Cancer & Research Questions
Role of Surgery in Cervical Cancer & Research Questions Arb-aroon Lertkhachonsuk, M.D., Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand Role of surgery in cervical cancer
More informationChapter 2: Initial treatment for endometrial cancer (including histologic variant type)
Chapter 2: Initial treatment for endometrial cancer (including histologic variant type) CQ01 Which surgical techniques for hysterectomy are recommended for patients considered to be stage I preoperatively?
More informationAdjuvant Therapies in Endometrial Cancer. Emma Hudson
Adjuvant Therapies in Endometrial Cancer Emma Hudson Endometrial Cancer Most common gynaecological cancer Incidence increasing in Western world 1-2% cancer deaths 75% patients postmenopausal 97% epithelial
More informationUpdate on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer
Update on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer Nicoletta Colombo, MD University of Milan-Bicocca European Institute of Oncology Milan, Italy NACT in Cervical Cancer NACT Stage -IB2 -IIA>4cm
More informationUPDATE IN THE MANAGEMENT OF INVASIVE CERVICAL CANCER
UPDATE IN THE MANAGEMENT OF INVASIVE CERVICAL CANCER Susan Davidson, MD Professor Department of Obstetrics and Gynecology Division of Gynecologic Oncology University of Colorado- Denver Anatomy Review
More informationSLN Mapping in Cervical Cancer. Memorial Sloan Kettering Cancer Center New York, USA
Lead Grou p Log SLN Mapping in Cervical Cancer Nadeem R. Abu-Rustum, M.D. Memorial Sloan Kettering Cancer Center New York, USA Conflict of Interest Disclosure Nadeem R. Abu-Rustum, M.D. I have no financial
More informationreceive adjuvant chemotherapy
Women with high h risk early stage endometrial cancer should receive adjuvant chemotherapy Michael Friedlander The Prince of Wales Cancer Centre and Royal Hospital for Women The Prince of Wales Cancer
More informationLocally advanced disease & challenges in management
Gynecologic Cancer InterGroup Cervix Cancer Research Network Cervix Cancer Education Symposium, February 2018 Locally advanced disease & challenges in management Carien Creutzberg Radiation Oncology, Leiden
More informationRole and Techniques of Surgery in Carcinoma Cervix. Dr Vanita Jain Additional Professor OBGYN PGIMER, Chandigarh
Role and Techniques of Surgery in Carcinoma Cervix Dr Vanita Jain Additional Professor OBGYN PGIMER, Chandigarh Points for Discussion Pattern of spread Therapeutic options Types of surgical procedures
More informationChapter 8 Adenocarcinoma
Page 80 Chapter 8 Adenocarcinoma Overview In Japan, the proportion of squamous cell carcinoma among all cervical cancers has been declining every year. In a recent survey, non-squamous cell carcinoma accounted
More informationStage IB1 (2-4 cm) Cervical cancer treated with Neoadjuvant chemotherapy followed by fertility Sparing Surgery (CONTESSA) Dre Marie Plante
Stage IB1 (2-4 cm) Cervical cancer treated with Neoadjuvant chemotherapy followed by fertility Sparing Surgery (CONTESSA) Dre Marie Plante Neo-Adjuvant Chemotherapy and Conservative Surgery in Cervical
More informationUpdate on Sentinel Node Biopsy in Endometrial Cancer: Feasibility, Technique, Impact
Update on Sentinel Node Biopsy in Endometrial Cancer: Feasibility, Technique, Impact Bjørn Hagen, MD, PhD St Olavs Hospital Trondheim University Hospital Trondheim, Norway Endometrial Cancer (EC) The most
More informationSession Number: 1020 Session: Adenocarcinoma of the Cervix: Diagnostic Pitfalls and New Prognostic Implications. Andres A. Roma, MD Cleveland Clinic
Session Number: 1020 Session: Adenocarcinoma of the Cervix: Diagnostic Pitfalls and New Prognostic Implications Andres A. Roma, MD Cleveland Clinic No Disclosures In the past 12 months, I have not had
More informationof surgical management of early invasive cervical cancer chapter Diagnosis and staging Wertheim described the principles
chapter 14. Surgical management of early invasive cervical cancer CHAPTER 1 Wertheim described the principles of surgical management of invasive cervical cancer more than 100 years ago in his treatise
More informationCervical Cancer 3/25/2019. Abnormal vaginal bleeding
Cervical Cancer Abnormal vaginal bleeding Postcoital, intermenstrual or postmenopausal Vaginal discharge Pelvic pain or pressure Asymptomatic In most patients who are not sexually active due to symptoms
More informationManagement of high risk early cervical cancer - a view of surgeon Dan DY Kim, M.D., Ph.D.
Management of high risk early cervical cancer - a view of surgeon Dan DY Kim, M.D., Ph.D. Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
More information17 th ESO-ESMO Masterclass in clinical Oncology
17 th ESO-ESMO Masterclass in clinical Oncology Cervical and endometrial Cancer Cristiana Sessa IOSI Bellinzona, Switzerland Berlin, March 28 th, 2018 Presenter Disclosures None Cervical Cancer Estimated
More informationFertility-sparing surgery in young patients with cervical cancer
Fertility-sparing surgery in young patients with cervical cancer Pr Catherine Uzan Chef de service Chirurgie et cancérologie gynécologique et mammaire, Pitié Evaluation BEFORE surgery Cancer: stage, type
More informationStaging and Treatment Update for Gynecologic Malignancies
Staging and Treatment Update for Gynecologic Malignancies Bunja Rungruang, MD Medical College of Georgia No disclosures 4 th most common new cases of cancer in women 5 th and 6 th leading cancer deaths
More informationThe Role of Radiation in the Management of Gynecologic Cancers. Scott Glaser, MD
The Role of Radiation in the Management of Gynecologic Cancers Scott Glaser, MD Nothing to disclose DISCLOSURE Outline The role of radiation in: Endometrial Cancer Adjuvant Medically inoperable Cervical
More informationEndometrial Cancer. Saudi Gynecology Oncology Group (SGOG) Gynecological Cancer Treatment Guidelines
Saudi Gynecology Oncology Group (SGOG) Gynecological Cancer Treatment Guidelines Endometrial Cancer Emad R. Sagr, MBBS, FRCSC Consultant Gynecology Oncology Security forces Hospital, Riyadh Epidemiology
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER CERVIX
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER CERVIX Site Group: Gynecology Cervix Author: Dr. Stephane Laframboise 1. INTRODUCTION 3 2. PREVENTION 3 3. SCREENING AND
More informationRitu Salani, M.D., M.B.A. Assistant Professor, Dept. of Obstetrics & Gynecology Division of Gynecologic Oncology The Ohio State University
Cervical Cancer Ritu Salani, M.D., M.B.A. Assistant Professor, Dept. of Obstetrics & Gynecology Division of Gynecologic Oncology The Ohio State University Estimated gynecologic cancer cases United States
More informationRisk group criteria for tailoring adjuvant treatment in patients with endometrial cancer : a validation study of the GOG criteria
Risk group criteria for tailoring adjuvant treatment in patients with endometrial cancer : a validation study of the GOG criteria Suk-Joon Chang, MD, Hee-Sug Ryu MD Gynecologic Cancer Center Department
More informationCervixcancer. Vad är aktuellt? Jan Persson. Lund. Docent överläkare Dep of OB&G Skane univ hosp Lund Sweden
Cervixcancer Copyright Jan Persson Lund Vad är aktuellt? Jan Persson Docent överläkare Dep of OB&G Skane univ hosp Lund Sweden Controversies Preop selection related stage ( stage 1b1>= 2 cm) Neoadjuvant
More informationA phase II study of weekly paclitaxel and cisplatin followed by radical hysterectomy in stages IB2 and IIA2 cervical cancer AGOG14-001/TGOG1008
A phase II study of weekly paclitaxel and cisplatin followed by radical hysterectomy in stages IB2 and IIA2 cervical cancer AGOG14-001/TGOG1008 NCT02432365 Chyong-Huey Lai, MD On behalf of Principal investigator
More informationICRT รศ.พญ.เยาวล กษณ ชาญศ ลป
ICRT รศ.พญ.เยาวล กษณ ชาญศ ลป Brachytherapy การร กษาด วยร งส ระยะใกล Insertion การสอดใส แร Implantation การฝ งแร Surface application การวางแร physical benefit of brachytherapy - very high dose of radiation
More informationIs Ovarian Preservation Feasible in Early-Stage Adenocarcinoma of the Cervix?
e-issn 1643-3750 DOI: 10.12659/MSM.897291 Received: 2015.12.27 Accepted: 2016.01.13 Published: 2016.02.08 Is Ovarian Preservation Feasible in Early-Stage Adenocarcinoma of the Cervix? Authors Contribution:
More informationNew Cancer Cases By Site Breast 28% Lung 14% Colo-Rectal 10% Uterus 6% Thyroid 5% Lymphoma 4% Ovary 3%
Uterine Malignancy New Cancer Cases By Site 2010 Breast 28% Lung 14% Colo-Rectal 10% Uterus 6% Thyroid 5% Lymphoma 4% Ovary 3% Cancer Deaths By Site 2010 Lung 26% Breast 15% Colo-Rectal 9% Pancreas 7%
More informationRelapse Patterns and Outcomes Following Recurrence of Endometrial Cancer in Northern Thai Women
DOI:http://dx.doi.org/10.7314/APJCP.2015.16.9.3861 Relapse Patterns and Outcomes Following Recurrence of Endometrial Cancer in Northern Thai Women RESEARCH ARTICLE Relapse Patterns and Outcomes Following
More informationPrognosis and recurrence pattern of patients with cervical carcinoma and pelvic lymph node metastasis
NJOG 2009 June-July; 4 (1): 19-24 Prognosis and recurrence pattern of patients with cervical carcinoma and pelvic lymph node metastasis Eliza Shrestha 1, Xiong Ying 1,2, Liang Li-Zhi 1,2, Zheng Min 1,2,
More informationIndex. B Bilateral salpingo-oophorectomy (BSO), 69
A Advanced stage endometrial cancer diagnosis, 92 lymph node metastasis, 92 multivariate analysis, 92 myometrial invasion, 92 prognostic factors FIGO stage, 94 histological grade, 94, 95 histologic cell
More informationENDOMETRIAL CANCER. Endometrial cancer is a great concern in UPDATE. For personal use only. Copyright Dowden Health Media
For mass reproduction, content licensing and permissions contact Dowden Health Media. UPDATE ENDOMETRIAL CANCER Are lymphadenectomy and external-beam radiotherapy valuable in women who have an endometrial
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Carcinoma of the Uterine Cervix
THIS DOCUMENT North of Scotland Cancer Network Carcinoma of the Uterine Cervix UNCONTROLLED WHEN PRINTED DOCUMENT CONTROL Prepared by A Kennedy/AG Macdonald/Others Approved by NOT APPROVED Issue date April
More informationStaging. Carcinoma confined to the corpus. Carcinoma confined to the endometrium. Less than ½ myometrial invasion. Greater than ½ myometrial invasion
5 th of June 2009 Background Most common gynaecological carcinoma in developed countries Most cases are post-menopausal Increasing incidence in certain age groups Increasing death rates in the USA 5-year
More informationGCIG Rare Tumour Brainstorming Day
GCIG Rare Tumour Brainstorming Day Relatively (Not So) Rare Tumours Adenocarcinoma of Cervix Keiichi Fujiwara, Ros Glasspool Benedicte Votan, Jim Paul Aim of the Day To develop at least one clinical trial
More informationLaparoscopic Management of Early Stage Endometrial Cancer. B. Rabischong, M. Canis, G. Le Bouedec, C. Pomel, J.L Achard, J. Dauplat, G.
Laparoscopic Management of Early Stage Endometrial Cancer B. Rabischong, M. Canis, G. Le Bouedec, C. Pomel, J.L Achard, J. Dauplat, G. Mage Early Stage of Endometrial Cancer most of cases diagnosed (clinical
More informationJanjira Petsuksiri, M.D
GYN malignancies Janjira Petsuksiri, M.D Outlines Cervical cancer Endometrial cancer Ovarian cancer Vaginal cancer Vulva cancer 2 CA Cervix Epidemiology - Second most common female cancer Risk factors
More informationAlgorithms for management of Cervical cancer
Algithms f management of Cervical cancer Algithms f management of cervical cancer are based on existing protocols and guidelines within the ESGO comunity and prepared by ESGO Educational Committe as a
More informationARROCase: Locally Advanced Endometrial Cancer
ARROCase: Locally Advanced Endometrial Cancer Charles Vu, MD (PGY-3) Faculty Advisor: Peter Y. Chen, MD, FACR Beaumont Health (Royal Oak, MI) November 2016 Case 62yo female with a 3yr history of vaginal
More informationPORTEC-4. Patient seqnr. Age at inclusion (years) Hospital:
May 2016 Randomisation Checklist Form 1, page 1 of 2 Patient seqnr. Age at inclusion (years) Hospital: Eligible patients should be registered and randomised via the Internet at : https://prod.tenalea.net/fs4/dm/delogin.aspx?refererpath=dehome.aspx
More informationCervical Cancer: 2018 FIGO Staging
Cervical Cancer: 2018 FIGO Staging Jonathan S. Berek, MD, MMS Laurie Kraus Lacob Professor Stanford University School of Medicine Director, Stanford Women s Cancer Center Senior Scientific Advisor, Stanford
More informationNAACCR Webinar Series /7/17
COLLECTING CANCER DATA: UTERUS 2017 2018 NAACCR WEBINAR SERIES Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching this webinar
More informationMRI for cervical and endometrial cancers. Dr Robert Bleehen Consultant Radiologist Cardiff & Vale UHB
MRI for cervical and endometrial cancers Dr Robert Bleehen Consultant Radiologist Cardiff & Vale UHB RCR 06(1) RCR 06(1) Technique Pelvic multiphased-array coil Fasting? Buscopan? ABDOMEN!!! Cx:+/- HR
More informationCervical cancer presentation
Carcinoma of the cervix: Carcinoma of the cervix is the second commonest cancer among women worldwide, with only breast cancer occurring more commonly. Worldwide, cervical cancer accounts for about 500,000
More informationMichael G. Kelly, MD Gynecologic Oncologist University of Colorado Cancer Center
Michael G. Kelly, MD Gynecologic Oncologist University of Colorado Cancer Center 50 yo healthy postmenopausal female with BMI = 35 with screening PAP smear = AGUS. What is the next step? (1) Colposcopy
More informationGynecologic Oncologist. Surgery Chemotherapy Radiation Therapy Hormonal Therapy Immunotherapy. Cervical cancer
Gynecologic Oncology Pre invasive vulvar, vaginal, & cervical disease Vulvar Cervical Endometrial Uterine Sarcoma Fallopian Tube Ovarian GTD Gynecologic Oncologist Surgery Chemotherapy Radiation Therapy
More informationGynecologic Cancer InterGroup Cervix Cancer Research Network. Management of Cervical Cancer in Resource Limited Settings.
Management of Cervical Cancer in Resource Limited Settings Linus Chuang MD Conflict of Interests None Cervical cancer is the fourth most common malignancy in women worldwide 530,000 new cases per year
More informationInternational prospective validation trial of sentinel node biopsy in cervical cancer
Cervix cancer committee International prospective validation trial of sentinel node biopsy in cervical cancer N Abu-Rustum, F Lécuru, P Mathevet, M Plante. F Bonnetain (Statistics) G Chatellier (Clinical
More informationSCBT.MR MRI of Uterine Malignancy. Susan M. Ascher, MD, FSCBT.MR Georgetown University School of Medicine Washington, DC
2 0 1 6 SCBT.MR MRI of Uterine Malignancy Susan M. Ascher, MD, FSCBT.MR Georgetown University School of Medicine Washington, DC aschers@gunet.georgetown.edu MUST READS Sala E, et al. The added role of
More informationEndometrial Cancer. Incidence. Types 3/25/2019
Endometrial Cancer J. Anthony Rakowski DO, FACOOG MSU SCS Board Review Coarse Incidence 53,630 new cases yearly 8,590 deaths yearly 4 th most common malignancy in women worldwide Most common GYN malignancy
More informationThe relationship between positive peritoneal cytology and the prognosis of patients with FIGO stage I/II uterine cervical cancer
Original Article J Gynecol Oncol Vol. 25,. 2:9-96 http://dx.doi.org/.382/jgo.24.25.2.9 pissn 25-38 eissn 25-399 The relationship between positive peritoneal cytology and the prognosis of patients with
More informationImpact of Surgery Extent on Survival and Recurrence Rate of Stage ⅠEndometrial Adenocarcinoma
Hou et al. / Cancer Cell Research 3 (2014) 65-69 Cancer Cell Research Available at http:// http://www.cancercellresearch.org/ ISSN 2161-2609 Impact of Surgery Extent on Survival and Recurrence Rate of
More informationCervical Cancer Guidelines L and SC Network July Introduction:
Cervical Cancer Guidelines L and SC Network July 2018 Introduction: There was a total number of 442 cases of cervix cancer diagnosed in Lancashire and South Cumbria Cancer Network in the period 2005 2009
More informationInfluence of Lymphadenectomy on Survival for Early-Stage Endometrial Cancer
Influence of Lymphadenectomy on Survival for Early-Stage Endometrial Cancer Jason D. Wright, MD, Yongemei Huang, MD/PhD, William M. Burke, MD, et al. Journal Club March 16, 2016 Blaine Campbell-PGY2 Objective
More informationEvolving Treatment Strategies for Cervical Cancer
Evolving Treatment Strategies for Cervical Cancer Nadeem Abu-Rustum, MD Memorial Sloan Kettering Cancer Center Evolving Treatment Strategies 1. Surgery 2. Radiation 3. Chemotherapy Incidence of cervix
More informationWhy Radical Trachelectomy and not Radical Hysterectomy for the treatment of early stage cervical cancer?
HJO An Obstetrics and Gynecology International Journal Review Why Radical Trachelectomy and not Radical Hysterectomy for the treatment of early stage cervical cancer? Nikolaos Thomakos 1, Sofia-Paraskevi
More informationPossibility of less radical treatment for patients with early invasive uterine cervical cancer
doi:10.1111/jog.12980 J. Obstet. Gynaecol. Res. Vol. 42, No. 7: 876 882, July 2016 Possibility of less radical treatment for patients with early invasive uterine cervical cancer Miseon Kim, Shinichi Ishioka,
More informationMRI in Cervix and Endometrial Cancer
28th Congress of the Hungarian Society of Radiologists RCR Session Budapest June 2016 MRI in Cervix and Endometrial Cancer DrSarah Swift St James s University Hospital Leeds, UK Objectives Cervix and endometrial
More information2009 USCAP Gyn Pathology Evening Session Case #3. Richard J. Zaino, MD Hershey Medical Center Penn State University Hershey, PA
2009 USCAP Gyn Pathology Evening Session Case #3 Richard J. Zaino, MD Hershey Medical Center Penn State University Hershey, PA rzaino@psu.edu Clinical history Middle aged woman with an exophytic mass of
More informationIntra-operative frozen section analysis of common iliac lymph nodes in patients with stage IB1 and IIA1 cervical cancer
Arch Gynecol Obstet (2012) 285:811 816 DOI 10.1007/s00404-011-2038-z GYNECOLOGIC ONCOLOGY Intra-operative frozen section analysis of common iliac lymph nodes in patients with stage IB1 and IIA1 cervical
More informationInvasive Cervical Cancer: Squamous Cell, Adenocarcinoma, Adenosquamous
Note: If available, clinical trials should be considered as preferred treatment options for eligible patients (www.mdanderson.org/gynonctrials). Other co-morbidities are taken into consideration prior
More informationAn Unusual Case of Cervical Cancer with Inguinal Lymph Node Metastasis: A Case Report and Review of the Literature
Archives of Clinical and Medical Case Reports doi: 10.26502/acmcr.9655003 Volume 1, Issue 1 Case Report An Unusual Case of Cervical Cancer with Inguinal Lymph Node Metastasis: A Case Report and Review
More informationGynecologic Cancers. What is Gynecologic Cancer. Who is at risk for GYN cancer? 3/1/2018 1
What is Gynecologic Cancer Gynecologic Cancers Marge Ramsdell RN, MN, OCN Madigan Army Medical Center Any cancer that starts in a woman s reproductive organs Each GYN cancer is unique 5 main types Cervical
More informationCorrelation of intermediate risk factors with prognostic factors in patients with early cervical cancer
대한부인종양콜포스코피학회제 24 차학술대회 Correlation of intermediate risk factors with prognostic factors in patients with early cervical cancer Seoul National University Bundang Hospital Eun Jung Soh, M.D. Cervical cancer
More informationJacqui Morgan March 6, 2019
Jacqui Morgan March 6, 2019 Case 1 25yo, G2P1 Here for WWE, no problems, healthy, needs refill on OCPs. Pap- Abnormal Glandular Cells-NOS Now What?? Case 1 Colposcopy What findings? Case 1 ECC Cervical
More informationECC or Margins Positive?
CLINICAL PRESENTATION This practice algorithm has been specifically developed for M. D. Anderson using a multidisciplinary approach and taking into consideration circumstances particular to M. D. Anderson,
More informationFertility Preventive Management In Gynecologic Cancers. Ateş Karateke, M.D. Professor of Obstetrics and Gynecology Zeynep Kamil Hospital ISTANBUL
Fertility Preventive Management In Gynecologic Cancers Ateş Karateke, M.D. Professor of Obstetrics and Gynecology Zeynep Kamil Hospital ISTANBUL All Cervical cancer cases 41% All Ovarian cancer cases 12%
More informationNeoadjuvant Treatment of. of Radiotherapy
Neoadjuvant Treatment of Breast Cancer: Role of Radiotherapy Neoadjuvant Chemotherapy Many new questions for radiation oncology? lack of path stage to guide indications should treatment response affect
More informationChemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer
Find Studies About Studies Submit Studies Resources About Site Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer The safety and scientific validity of this study is
More informationShould the Optimal Adjuvant Treatment for Patients With Early-Stage Endometrial Cancer With High-Intermediate Risk Factors Depend on Tumor Grade?
ORIGINAL STUDY Should the Optimal Adjuvant Treatment for Patients With Early-Stage Endometrial Cancer With High-Intermediate Risk Factors Depend on Tumor Grade? Chunyan Lan, MD,* Xin Huang, MD,* Qidan
More informationClinical Significance of Sentinel Lymph Nodes in Patients with Endometrial Cancer
KSGO 2014 Clinical Significance of Sentinel Lymph Nodes in Patients with Endometrial Cancer Daisuke Aoki, M.D., Ph.D. Chairman and Professor, Department of Obstetrics and Gynecology, School of Medicine,
More informationUterine Cervix. Protocol applies to all invasive carcinomas of the cervix.
Uterine Cervix Protocol applies to all invasive carcinomas of the cervix. Protocol revision date: January 2005 Based on AJCC/UICC TNM, 6 th edition and FIGO 2001 Annual Report Procedures Cytology (No Accompanying
More informationWhy Do Axillary Dissection? Nodal Treatment and Survival NSABP B04. Revisiting Axillary Dissection for SN Positive Patients
Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York, NY 10065 10th International Congress on the Future of Breast Cancer Coronado, CA Why Do Axillary Dissection? 6 August 2011 Implications
More informationIndependent risk factors for ovarian metastases in stage IA IIB cervical carcinoma
Received: 10 January 2018 Revised: 8 August 2018 Accepted: 13 August 2018 DOI: 10.1111/aogs.13442 ORIGINAL RESEARCH ARTICLE Independent risk factors for ovarian metastases in stage IA IIB cervical carcinoma
More informationPrognostic significance of positive lymph node number in early cervical cancer
1052 Prognostic significance of positive lymph node number in early cervical cancer JUNG WOO PARK and JONG WOON BAE Department of Obstetrics and Gynecology, Dong A University Hospital, Dong A University
More informationTumor volume and lymphovascular space invasion as a prognostic factor in early invasive adenocarcinoma of the cervix
Original Article J Gynecol Oncol Vol. 23, No. 3:153-158 pissn 2005-0380 eissn 2005-0399 Tumor volume and lymphovascular space invasion as a prognostic factor in early invasive adenocarcinoma of the cervix
More informationImplications of ACOSOG Z11 for Clinical Practice: Surgical Perspective
Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York, NY 10065 10th International Congress on the Future of Breast Cancer Coronado, CA 6 August 2011 Implications of ACOSOG Z11 for Clinical
More informationCARCINOMA CERVIX. Dr. PREETHI REDDY. B. M S OBG II yr POST GRADUATE.
CARCINOMA CERVIX Dr. PREETHI REDDY. B M S OBG II yr POST GRADUATE. Introduction Cervical cancer is the second most common female malignancy worldwide. It is responsible for 4,66,000 deaths annually worldwide
More informationPET/CT in Gynaecological Cancers. Stroobants Sigrid, MD, PhD Departement of Nuclear Medicine University Hospital,Antwerp
PET/CT in Gynaecological Cancers Stroobants Sigrid, MD, PhD Departement of Nuclear Medicine University Hospital,Antwerp Cervix cancer Outline of this talk Initial staging Treatment monitoring/guidance
More informationMANAGEMENT OF CERVICAL CANCER
MANAGEMENT OF CERVICAL CANCER Dr. Ujeen Shrestha Malla* and Prof. Dr. Zhang Shui Rong Department of Obstetrics and Gynaecology, Clinical Medical College of Yangtze University, Jingzhou Central Hospital,
More informationSurgical Progress in the Management in Gynecologic Cancers
Surgical Progress in the Management in Gynecologic Cancers Stephen J. Lee, MD Assistant Professor stelee@coh.org September 19, 2018 Nothing to disclose DISCLOSURE Defining Minimally Invasive Surgery: Hysterectomy
More informationENDOMETRIAL CANCER Updated Apr 2017 by: Dr. Jenny Ko (Medical Oncologist, Abbotsford Cancer Centre)
ENDOMETRIAL CANCER Updated Apr 2017 by: Dr. Jenny Ko (Medical Oncologist, Abbotsford Cancer Centre) Source: UpToDate 2017, ASCO/CCO/Alberta provincial guidelines, NCCN Reviewed by: Dr. Sarah Glaze (Gynecologic
More information3/25/2019. Rare uterine cancers ~3% Leiomyosarcoma Carcinosarcoma (MMMT) Endometrial Stromal Sarcomas Aggressive tumors High Mortality Rates
J. Anthony Rakowski D.O., F.A.C.O.O.G. MSU SCS Board Review Coarse Rare uterine cancers ~3% Leiomyosarcoma Carcinosarcoma (MMMT) Endometrial Stromal Sarcomas Aggressive tumors High Mortality Rates Signs
More informationSentinel Lymph Node Biopsy Is Valuable For All Cancer. Surgery Grand Rounds Debate October 6, 2008 Joel Baumgartner
Sentinel Lymph Node Biopsy Is Valuable For All Cancer Surgery Grand Rounds Debate October 6, 2008 Joel Baumgartner History Lymphatics first described by Rasmus Bartholin in 1653 Rudolf Virchow postulated
More informationFERTILITY SPARING IN ENDOMETRIAL CANCER
FERTILITY SPARING IN ENDOMETRIAL CANCER Prof. Dr. Bülent Özçelik Erciyes University Medical Faculty Department of Obstetrics and Gynecology Gynecologic Oncology Unit Endometrial Cancer Most frequent gynecologic
More informationUTERINE SARCOMA EXAMPLE OF A UTERINE SARCOMA USING PROPOSED TEMPLATE
UTERINE SARCOMA EXAMPLE OF A UTERINE SARCOMA USING PROPOSED TEMPLATE Case: Adenosarcoma with heterologous elements and stromal overgrowth o TAH, BSO, omentectomy, staging biopsies of cul-de-sac, bladder
More informationFactors associated with parametrial involvement in patients with stage IB1 cervical cancer: who is suitable for less radical surgery?
Original Article Obstet Gynecol Sci 2018;61(1):88-94 https://doi.org/10.5468/ogs.2018.61.1.88 pissn 2287-8572 eissn 2287-8580 Factors associated with parametrial involvement in patients with stage IB1
More informationProf. Dr. Aydın ÖZSARAN
Prof. Dr. Aydın ÖZSARAN Adenocarcinomas of the endometrium Most common gynecologic malignancy in developed countries Second most common in developing countries. Adenocarcinomas, grade 1 and 2 endometrioid
More informationPara-aortic laparoscopic lymph-node dissection for advanced cervical cancers
Para-aortic laparoscopic lymph-node dissection for advanced cervical cancers P. Mathevet, Hôpital Femme-Mère-Enfant, Bron Lymph-node involvement Is one of the major prognostic factor in gynecologic cancers.
More informationDivision of Radiation Oncology, Groote Schuur Hospital and University of Cape Town, Cape Town, South Africa b
Southern African Journal of Gynaecological Oncology 2018; 1(1):1 5 https://doi.org/10.1080/20742835.2018.1467998 Open Access article distributed under the terms of the Creative Commons License [CC BY-NC
More informationIntention-to-Treat Analysis of Radical Trachelectomy for Early-Stage Cervical Cancer With Special Reference to Oncologic Failures
ORIGINAL STUDY Intention-to-Treat Analysis of Radical Trachelectomy for Early-Stage Cervical Cancer With Special Reference to Oncologic Failures Single-Institutional Experience in Hungary Robert Póka,
More informationEnterprise Interest None
Enterprise Interest None Cervical Cancer -Management of late stages ESP meeting Bilbao Spain 2018 Dr Mary McCormack PhD FRCR Consultant Clinical Oncologist University College Hospital London On behalf
More informationOncologic effectiveness of nerve-sparing radical hysterectomy in cervical cancer
J Gynecol Oncol. 2018 May;29(3):e41 pissn 2005-0380 eissn 2005-0399 Original Article Oncologic effectiveness of nerve-sparing radical hysterectomy in cervical cancer Antonino Ditto, Giorgio Bogani, Umberto
More informationTae-Wook Kong 1,2, Joo-Hyuk Son 1,2, Jiheum Paek 1,2, Yonghee Lee 1,3, Eun Ju Lee 1,4, Suk-Joon Chang 1,2, Hee-Sug Ryu 1,2
Preoperative nomogram for individualized prediction of parametrial invasion in patients with FIGO stage IB cervical cancer treated with radical hysterectomy Tae-Wook Kong 1,2, Joo-Hyuk Son 1,2, Jiheum
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,800 116,000 120M Open access books available International authors and editors Downloads Our
More information